NANALYSIS SCIENTIFIC CORP. Financials Nanalysis Scientific Corp. OTC Markets
Equities
NSCIF
CA63000Y1034
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2851 USD | -5.91% |
|
-6.31% | +2.55% |
| May. 30 | Transcript : Nanalysis Scientific Corp., Q1 2024 Earnings Call, May 30, 2024 | |
| May. 29 | Transcript : Nanalysis Scientific Corp., Q1 2024 Earnings Call, May 29, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 29.57 | 31.37 | 111.4 | 68.83 | 38.08 |
| Enterprise Value (EV) 1 | 24.46 | 31.98 | 107 | 76.05 | 59.29 |
| P/E ratio | -16 x | -7.92 x | -48.3 x | -7.3 x | -2.3 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 3.54 x | 3.98 x | 6.94 x | 2.77 x | 1.34 x |
| EV / Revenue | 2.92 x | 4.06 x | 6.67 x | 3.06 x | 2.08 x |
| EV / EBITDA | 50.5 x | -10.7 x | -186 x | -8.64 x | -4.49 x |
| EV / FCF | -31.6 x | -26.3 x | -30.5 x | -5.95 x | -7.41 x |
| FCF Yield | -3.17% | -3.8% | -3.28% | -16.8% | -13.5% |
| Price to Book | 1.98 x | 2.19 x | 4.67 x | 1.96 x | 1.63 x |
| Nbr of stocks (in thousands) | 61,611 | 66,035 | 76,829 | 94,282 | 101,544 |
| Reference price 2 | 0.4800 | 0.4750 | 1.450 | 0.7300 | 0.3750 |
| Announcement Date | 4/22/20 | 4/22/21 | 4/28/22 | 4/27/23 | 4/29/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 8.381 | 8.364 | 7.874 | 16.04 | 24.82 | 28.47 |
| EBITDA 1 | 0.2467 | 0.484 | -2.996 | -0.574 | -8.805 | -13.21 |
| EBIT 1 | 0.04 | 0.058 | -3.741 | -1.191 | -10.06 | -13.54 |
| Operating Margin | 0.48% | 0.69% | -47.51% | -7.42% | -40.51% | -47.55% |
| Earnings before Tax (EBT) 1 | 0.1355 | -1.399 | -3.975 | -1.772 | -10.4 | -16.8 |
| Net income 1 | 0.0735 | -1.66 | -3.678 | -1.772 | -9.101 | -16.2 |
| Net margin | 0.88% | -19.85% | -46.71% | -11.05% | -36.67% | -56.9% |
| EPS 2 | 0.000885 | -0.0300 | -0.0600 | -0.0300 | -0.1000 | -0.1633 |
| Free Cash Flow 1 | -2.73 | -0.7748 | -1.215 | -3.506 | -12.78 | -7.996 |
| FCF margin | -32.57% | -9.26% | -15.43% | -21.86% | -51.5% | -28.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/24/19 | 4/22/20 | 4/22/21 | 4/28/22 | 4/27/23 | 4/29/24 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.077 | 5.554 | 5.187 | 6.878 | 7.203 | 4.674 | 6.956 | 7.036 | 9.8 | 11.16 |
| EBITDA 1 | 0.413 | 0.21 | -0.947 | -0.618 | -2.58 | -3.547 | -2.399 | -1.354 | -0.774 | -0.362 |
| EBIT | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/28/22 | 5/30/22 | 8/25/22 | 11/29/22 | 4/27/23 | 5/25/23 | 8/24/23 | 11/29/23 | 4/29/24 | 5/29/24 |
1CAD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.22 | - | 0.62 | - | 7.23 | 21.2 |
| Net Cash position 1 | - | 5.11 | - | 4.42 | - | - |
| Leverage (Debt/EBITDA) | 0.8877 x | - | -0.2063 x | - | -0.8209 x | -1.606 x |
| Free Cash Flow 1 | -2.73 | -0.77 | -1.22 | -3.51 | -12.8 | -8 |
| ROE (net income / shareholders' equity) | 1.08% | -14.1% | -25% | -9.25% | -27.7% | -47.2% |
| ROA (Net income/ Total Assets) | 0.26% | 0.25% | -11.1% | -2.41% | -11.7% | -13.7% |
| Assets 1 | 28.29 | -669.9 | 33.27 | 73.54 | 77.98 | 118.4 |
| Book Value Per Share 2 | 0.1000 | 0.2400 | 0.2200 | 0.3100 | 0.3700 | 0.2300 |
| Cash Flow per Share 2 | 0.0100 | 0.1100 | 0.0500 | 0.1300 | 0.0400 | 0.0100 |
| Capex 1 | 0.8 | 0.55 | 0.43 | 0.6 | 2.13 | 0.73 |
| Capex / Sales | 9.6% | 6.52% | 5.42% | 3.71% | 8.57% | 2.56% |
| Announcement Date | 5/24/19 | 4/22/20 | 4/22/21 | 4/28/22 | 4/27/23 | 4/29/24 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.77% | 210B | |
| +8.83% | 186B | |
| +31.94% | 158B | |
| +33.19% | 113B | |
| +4.79% | 66.13B | |
| +22.41% | 56.25B | |
| +1.34% | 49B | |
| -5.92% | 38.16B | |
| +1.94% | 35.98B |
- Stock Market
- Equities
- NSCI Stock
- NSCIF Stock
- Financials Nanalysis Scientific Corp.
